Quanterix Corporation
QTRX Healthcare Medical Devices
Quanterix Corporation’s revenue for fiscal 2025 (year ended December 2025) was $138.9 million, up 1.07% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS fell 35.1% and free cash flow grew 18.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow QTRX
Quanterix Corporation (QTRX) Piotroski F-score
Quanterix Corporation's Piotroski F-score for fiscal 2025 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 3 | 0.00 |
| FY2024 | 3 | (2.00) |
| FY2023 | 5 | 2.00 |
| FY2022 | 3 | (1.00) |
| FY2021 | 4 | 0.00 |
| FY2020 | 4 | (1.00) |
| FY2019 | 5 | 1.00 |
| FY2018 | 4 | 0.00 |
| FY2017 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (25.97%) | (9.23%) | Fail | 0 |
| Positive operating cash flow | (77.24m) | (35.16m) | Fail | 0 |
| Rising return on assets | (25.97%) | (9.23%) | Fail | 0 |
| Cash flow above net income | 29.91m | 3.37m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 2.84 | 8.66 | Fail | 0 |
| No new shares issued | 42,639,000 | 38,367,000 | Fail | 0 |
| Rising gross margin | 46.77% | 60.47% | Fail | 0 |
| Rising asset turnover | 0.34 | 0.33 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| INGN Inogen, Inc compare | 5 |
| STIM Neuronetics, Inc. compare | 4 |
| ZOMDF Zomedica Corp. compare | 4 |
| OWLT Owlet, Inc. compare | 4 |
| LUCD Lucid Diagnostics Inc. compare | 4 |
| APYX Apyx Medical Corporation compare | 4 |
| QTRX Quanterix Corporation | 3 |
| RXST RxSight, Inc. compare | 3 |
| MXCT MaxCyte, Inc. compare | 2 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover